Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | LIPC | P11150 | 2/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563776 | 0.87 | GRIK1 (0.43) | GPR6ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3557510 | 0.86 | GPR6 (0.35) | GPR6PDE4BGRIK1GRIA2 | |
| SCHEMBL3905636 | 0.80 | GPR6 (0.41) | GPR6ALDH1A1KDM4EHPGDPDE4B | |
| SCHEMBL8094956 | 0.79 | LIPG (0.38) | LIPGLIPC | |
| SCHEMBL3554378 | 0.78 | MEN1 (0.37) | GPR6ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3912796 | 0.77 | GPR6 (0.38) | GPR6ALDH1A1KDM4EHPGDPDE4B | |
| SCHEMBL3151575 | 0.77 | PDE4B (0.50) | KDM4EPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL9013863 | 0.72 | GPR119 (0.38) | — | |
| SCHEMBL7356525 | 0.71 | HIF1A (0.34) | GPR6ALDH1A1PDE4BPDE4APDE4C | |
| SCHEMBL7342824 | 0.69 | OXTR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | GPR6 2624/4885ALDH1A1 458/4885TDP1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.